UNIT 2. Drug Distribution. S. SANGEETHA., M.PHARM., (Ph.d) Department of Pharmaceutics SRM College of Pharmacy SRM University

Size: px
Start display at page:

Download "UNIT 2. Drug Distribution. S. SANGEETHA., M.PHARM., (Ph.d) Department of Pharmaceutics SRM College of Pharmacy SRM University"

Transcription

1 UNIT 2 Drug Distribution S. SANGEETHA., M.PHARM., (Ph.d) Department of Pharmaceutics SRM College of Pharmacy SRM University

2 Contents Definition Factors affecting drug distribution a) Tissue permeability of the drug b) Organ/tissue size and perfusion rate c) Binding of drugs to tissue components d) Miscellaneous Volume of distribution Significance One compartment open model Non compartment method References

3 Definition Drug distribution is defined as the reversible transfer of drug between one compartment(blood) and another (extra vascular tissue)

4 Steps in drug distribution Permeation of free drug through capillary wall & entry in to ECF. Permeation of drugs from ECF to ICF through membrane of tissue cell. Rate limiting steps Rate of perfusion to the ECF Membrane permeability of the drug

5 Factors affecting distribution of drugs 1. Tissue permeability of drugs 2. Organ tissue size and perfusion rate 3. Binding of drug to tissue component. 4. Miscellaneous

6 Tissue permeability of drugs Physicochemical properties of the drug molecular size, pka and o/w partition co efficient. Physiological barrier to diffusion Simple capillary endothelial barrier Simple cell membrane barrier Blood Brain Barrier Blood CSF barrier Blood placental barrier blood testis barrier

7 Physicochemical properties of the drug: Molecular size: < d easily cross capillary membrane, water soluble molecules & ions of size < 50 d pass through aq. Filled channels. pka : ph of blood & ECF (7.4) play a role in degree of ionization, unionized drug diffuse rapidly. o/w partition co efficient: lipoidal drug penetrate the tissue rapidly. Among Drugs with same K0/w but diff in ionization of blood ph. The one which has less ionization show better distribution. E.g. Phenobarbital > salicylic acid

8 Physiological barrier to the diffusion: Simple capillary endothelial barrier: drugs with molecular size < 600 d easily diffuse. The simple cell membrane barrier : it is similar to the lipoidal barrier in the GI absorption of the drugs. B.B.B: highly specialized and less permeable to water soluble drugs. Brain capillary consist of endothelial cells which are joined one another by continuous tight intercellular junctions. Pericytes & astrocytes form a solid envelop around brain capillary & block intercellular passage.

9 Physiological barrier to the diffusion: A solute may enter to brain via: 1. Passive diffusion through the lipoidal barrier 2. Active transport of essential nutrients BBB crossing can be promoted by: 1. Use of permeation enhancer like DMSO. 2. Osmotic disruption of the BBB by infusing internal carotid artery with Mannitol 3. Use of dihydropyridine redox system as a drug carriers

10 Physiological barrier to the diffusion: Blood cerebrospinal fluid barrier: formed by the choroid plexus of the lateral, third & fourth ventricles. It is similar to ECF of brain. The capillary endothelium that line choroid plexus have open junctions or gaps and drugs can flow freely. The choroid cells are joined to each other by tight junctions forming the blood CSF barrier which has permeability characteristic similar to BBB. For any given drug, its conc in brain > in the CSF.

11 Physiological barrier to the diffusion: Blood placental barrier: The maternal & fetal blood vessels are separated by a number of tissue layers made of fetal trophoblast basement membrane &endothelium which together constitute the placental barrier. Drugs having molecular size less than 1000 d and moderate lipid solubility cross the placental barrier. E.g. ethanol, sulphonamide, barbiturate, Narcotic analgesic, anticonvulsant etc.

12 Physiological barrier to the diffusion: Blood testis barrier: Located not at the capillary endothelium level but at the sertoli sertoli cell junction. It is tight junction between neighboring sertoli cells that act as barrier. It restrict the passage of drugs to spermatocyte and spermatids.

13 Organ/Tissue size & perfusion rate Distribution is permeability related in following cases When the drug is ionic/polar/water soluble Where the highly selective physiology barrier restrict the diffusion of such drugs to the inside of cell. Distribution bill be perfusion rate limited When the drug is highly lipohilic When the membrane is highly permeable.

14 Perfusion rate : it is defined as the volume of the blood that flows per unit time per unit volume of the tissue. Unit: ml/min/ml Kt = perfusion rate / Kt/b Distribution half life = 0.693/Kt =0.693Kt/b/perfusion rate

15 Binding of drug to tissue components Binding of drugs to blood components o Blood cells o Plasma proteins Binding of drugs to extra vascular tissues

16 Binding of drugs to blood cells The major component of blood is RBC The RBC comprises of 3 components each of which can bind to drugs: hemoglobin carbonic anhydrase cell membrane

17 Binding of drugs to plasma proteins Plasma protein drug binding: The binding of drug to plasma protein is reversible The extent or order of binding of drugs to various plasma proteins is: Albumin >α 1 Acid Glycoprotein> Lipoproteins > Globulins

18 Binding of drug to Human serum Albumin: Most abundant plasma protein with large drug binding capacity Both endogenous compounds and drugs bind to HSA Four different sites on HSA: Site I: warfarin and azapropazone binding site Site II: diazepam binding site Site III: digitoxin binding site Site IV: tamoxifen binding site

19 Binding of dugs to α 1 Acid Glycoprotein: it binds to basic drugs like imipramine, amitryptyline, lidocaine Binding of dugs to lipoproteins: a drug that binds to lipoproteins does so by dissolving in the lipid core of the protein and thus its capacity to bind depends upon its lipid content. binding of drugs to lipoproteins is non competitive

20 Miscellaneous factors Age: a) Total body water b) Fat content c) Skeletal muscles d) Organ composition e) Plasma protein content Pregnancy Obesity Diet Disease states

21 Volume of distribution The apparent volume of distribution is a proportionality constant relating the plasma concentration to the total amount of drug in the body. XαC X=Vd.C Vd=X/C Apparent volume =amount of drug in the body/ of distribution plasma drug concentration

22 Significance Apparent volume of distribution is dependent on concentration of drug in plasma. Drugs with a large apparent volume are more concentrated in extra vascular tissues and less concentrated intravascular. In certain pathological cases, the Vd for the drug may be altered if the distribution of the drug is changed.

23 One compartmental open model Vd=X/C Vd=X 0 /C o =i.v.bolus dose/concentration of drug in plasma

24 Non compartmental method for drugs given as i.v. bolus: Vd (area) =X0/K E (AUC) For drugs administered extravascularly: Vd (area) = FXo/K E (AUC)

25 References Applied biopharmaceutics and pharmacokinetics by Leon Shargel Clinical biopharmaceutics and pharmacokinetics by Gibaldi biopharmaceutics and pharmacokinetics by Brahmankar

PHARMACOKINETICS. Dr. M.Mothilal Assistant professor

PHARMACOKINETICS. Dr. M.Mothilal Assistant professor PHARMACOKINETICS Dr. M.Mothilal Assistant professor 1 OVERVIEW Basic considerations in pharmacokinetics Compartment models One compartment model Assumptions Intravenous bolus administration Intravenous

More information

BASIC PHARMACOKINETICS AND PHARMACODYNAMICS

BASIC PHARMACOKINETICS AND PHARMACODYNAMICS BASIC PHARMACOKINETICS AND PHARMACODYNAMICS An Integrated Textbook and Computer Simulations SARA ROSENBAUM ~ WILEY A lohn WILEY & SONS, INC., PUBLICATION CONTENTS Preface 1 Introduction to Pharmacokinetics

More information

Expert Intelligence for Better Decisions Macrocycles:

Expert Intelligence for Better Decisions Macrocycles: Expert Intelligence for Better Decisions Macrocycles: Discovery, Development & Technologies Using This Document Insight Pharma Reports are interactive electronic documents which offer many of the features

More information

How do drugs work? Part 1. PK: Principles & Processes. PK vs. PD. Pharmacokinetics : Basic Principles Overview. What does the body do to a drug?

How do drugs work? Part 1. PK: Principles & Processes. PK vs. PD. Pharmacokinetics : Basic Principles Overview. What does the body do to a drug? Pharmacokinetics : Basic Principles verview 1. PK : Basic principles and processes 2. Important PK Parameters 3. Modulating PK Parameters 4. PK : Drugs vs. contrast agents Twan Lammers Dept. of Experimental

More information

INTRODUCTION TO CLINICAL PHARMACY

INTRODUCTION TO CLINICAL PHARMACY CHAPTER 1 INTRODUCTION TO CLINICAL PHARMACY Clinical pharmacy is the branch of Pharmacy where pharmacists provide patient care that optimizes the use of medication and promotes health, wellness, and disease

More information

BIOPHARMACEUTICS AND PHARMACOKINETICS

BIOPHARMACEUTICS AND PHARMACOKINETICS BIOPHARMACEUTICS AND PHARMACOKINETICS (JULIO 2015) Degree in PHARMACY University of Alcalá Academic year 2015/16 3 rd Year 1 st Season COURSE DESCRIPTION Title: Biopharmaceutics and Pharmacokinetics Code:

More information

BIOPHARMACEUTICS AND PHARMACOKINETICS. University of Alcalá. Academic year 2016/17 3 rd Year 1 st Season

BIOPHARMACEUTICS AND PHARMACOKINETICS. University of Alcalá. Academic year 2016/17 3 rd Year 1 st Season BIOPHARMACEUTICS AND PHARMACOKINETICS Degree in PHARMACY University of Alcalá Academic year 2016/17 3 rd Year 1 st Season COURSE DESCRIPTION Title: Biopharmaceutics and Pharmacokinetics Code: 570014 Degree:

More information

Abstract. Technical Aspects. Applying GastroPlus for Extensions of Biowaivers for BCS Class II Compounds 2

Abstract. Technical Aspects. Applying GastroPlus for Extensions of Biowaivers for BCS Class II Compounds 2 Abstract GastroPlus is a mechanistically based simulation software package that predicts absorption, pharmacokinetics, and pharmacodynamics in humans and animals. GastroPlus modeling and simulation has

More information

The Challenges of Designing Cyclic Prodrugs of Opioid Peptides that Permeate the Intestinal Mucosa and the Blood-Brain Barrier

The Challenges of Designing Cyclic Prodrugs of Opioid Peptides that Permeate the Intestinal Mucosa and the Blood-Brain Barrier The Challenges of Designing Cyclic Prodrugs of pioid Peptides that Permeate the Intestinal Mucosa and the Blood-Brain Barrier Ronald T. Borchardt Department of Pharmaceutical Chemistry The University of

More information

2. Relay characteristics of proteins and protein electrophoresis / fractionation.

2. Relay characteristics of proteins and protein electrophoresis / fractionation. UNIT: Proteins 15prot_elec.wpd Task Electrophoresis Objectives Upon completion of this exercise, the student will be able to: 1. Review electrophoresis information as presented in class. 2. Relay characteristics

More information

Veins Valves prevent engorgement and backflow. Baroreceptor reflex. Veins returning blood

Veins Valves prevent engorgement and backflow. Baroreceptor reflex. Veins returning blood Veins have large radii and low resistance. Walls are thin, not elastic Most blood volume is in veins Veins returning blood Veins Valves prevent engorgement and backflow Sympathetic NS constricts veins

More information

On applications of conservation laws in pharmacokinetics

On applications of conservation laws in pharmacokinetics On applications of conservation laws in pharmacokinetics S.Piekarski (1), M.Rewekant (2) Institute of Fundamental Technological Research Polish Academy of Sciences (1), Medical University of Warsaw, Poland

More information

These handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides.

These handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides. These handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides. If you would like the 1 slide per page handouts, please ask

More information

Model-based Technology Selection for Bioavailability Enhancement CPHI DAVID K. LYON, PH.D. OCTOBER 25, 2017

Model-based Technology Selection for Bioavailability Enhancement CPHI DAVID K. LYON, PH.D. OCTOBER 25, 2017 Model-based Technology Selection for Bioavailability Enhancement CPHI DAVID K. LYON, PH.D. OCTOBER 25, 2017 Biopharmaceutical Classification System Approximately 80% of drugs in the pharmaceutical compounds

More information

Pre-Analytic Issues in Laboratory Medicine

Pre-Analytic Issues in Laboratory Medicine Pre-Analytic Issues in Laboratory Medicine Daniel J. Fink, MD, MPH Director, Core Laboratory New York Presbyterian hospital Columbia University Medical Center October 3, 2006 Learning Objectives Pre-Analytic

More information

Design and Dosage Form. Dr. Deny Susanti

Design and Dosage Form. Dr. Deny Susanti Design and Dosage Form Dr. Deny Susanti Example 1 Aspirin tablet is stable but not as a liquid dosage form How to design liquid form? Soluble or dispersible aspirin tablets-to be dissolved in water Note:

More information

The Hollow Fiber Bioreactor and Cell Co-Cultivation

The Hollow Fiber Bioreactor and Cell Co-Cultivation The Hollow Fiber Bioreactor and Cell Co-Cultivation June 12, 2012 John J.S. Cadwell Historically, the scientific method had been based upon the reduction of complex systems to their simplest forms in order

More information

PK and PK/PD Guided Starting Dose Selection for First-In-Human Trials. Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis

PK and PK/PD Guided Starting Dose Selection for First-In-Human Trials. Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis PK and PK/PD Guided Starting Dose Selection for First-In-Human Trials Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis Disclaimer Contents are the opinion of the author and not that of Novartis

More information

RAM Direct Injection. (Restricted Access Media) A Tool for the Separation of Small Molecules in the Presence of Large Biomolecules

RAM Direct Injection. (Restricted Access Media) A Tool for the Separation of Small Molecules in the Presence of Large Biomolecules RAM Direct Injection (Restricted Access Media) A Tool for the Separation of Small Molecules in the Presence of Large Biomolecules HPLC analysis of small molecules contained within a protein matrix can

More information

How to Measure Drug Transport across the Blood-Brain Barrier

How to Measure Drug Transport across the Blood-Brain Barrier NeuroRx : The Journal of the American Society for Experimental NeuroTherapeutics How to Measure Drug Transport across the Blood-Brain Barrier Ulrich Bickel Department of Pharmaceutical Sciences, Texas

More information

ICH Guideline S3A: Note for guidance on toxicokinetics: the assessment of systemic exposure in toxicity studies - questions and answers

ICH Guideline S3A: Note for guidance on toxicokinetics: the assessment of systemic exposure in toxicity studies - questions and answers 14 December EMA/CHMP/ICH/320985/2016 Committee for Medicinal Products for Human Use ICH Guideline S3A: Note for guidance on toxicokinetics: the assessment of systemic exposure in toxicity studies - questions

More information

Study (s) Degree Center Acad. Period Grado de Farmacia FACULTY OF PHARMACY 3 Annual PDG Farmacia-Nutrición Humana y Dietética

Study (s) Degree Center Acad. Period Grado de Farmacia FACULTY OF PHARMACY 3 Annual PDG Farmacia-Nutrición Humana y Dietética COURSE DATA Data Subject Code 34081 Name Biopharmacy and Pharmacokinetics Cycle Grade ECTS Credits 10.5 Academic year 2014-2015 Study (s) Degree Center Acad. Period year 1201 - Grado de Farmacia FACULTY

More information

Cells and Tissues. Overview CELLS

Cells and Tissues. Overview CELLS Cells and Tissues WIll The basic unit of structure and function in the human body is the cell. Each of a cell's parts, or organelles, as well as the entire cell, is organized to perform a specific function.

More information

Syringe Pumps. Please contact us for help in selecting the best pump for your application and a free quote.

Syringe Pumps. Please contact us for help in selecting the best pump for your application and a free quote. Syringe Pumps Microfluidic Pumps! We are proud to offer select Harvard Apparatus syringe pumps for use with SynVivo biochips. These high quality pumps have been extensively tested and offer a feature rich

More information

QUESTIONS AND ANSWERS TO ICH S3A: NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT OF SYSTEMIC EXPOSURE IN TOXICITY STUDIES FOCUS ON MICROSAMPLING

QUESTIONS AND ANSWERS TO ICH S3A: NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT OF SYSTEMIC EXPOSURE IN TOXICITY STUDIES FOCUS ON MICROSAMPLING INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE QUESTIONS AND ANSWERS TO ICH S3A: NOTE FOR GUIDANCE ON TOXICOKINETICS: THE ASSESSMENT

More information

Small Interfering RNA s Molecular biology and use in therapy

Small Interfering RNA s Molecular biology and use in therapy Small Interfering RNA s Molecular biology and use in therapy Dr Stuart Hamilton - NHMRC Early Career Fellow Serology and Virology Division, SEALS Microbiology, Prince of Wales Hospital; School of Women

More information

ProSEC 300S. Protein Characterization columns

ProSEC 300S. Protein Characterization columns ProSEC 300S Protein Characterization columns Agilent s ProSEC 300S is a silica-based material specifically designed for the analysis of proteins by aqueous size exclusion chromatography. With a proprietary

More information

Microbial Growth and The Control of Microbial Growth (Chapter 6 & 7)

Microbial Growth and The Control of Microbial Growth (Chapter 6 & 7) Microbial Growth and The Control of Microbial Growth (Chapter 6 & 7) Lecture Materials for Amy Warenda Czura, Ph.D. Suffolk County Community College Eastern Campus Primary Source for figures and content:

More information

Antibodies and Antigens In the blood bank

Antibodies and Antigens In the blood bank Antibodies and Antigens In the blood bank 1 Nice game!! http://nobelprize.org/ 2 Karl Landsteiner discovered blood groups in 1901. Awarded Nobel Prize for Physiology or Medicine in 1930 3 Why we study

More information

Controlled Release Drug Delivery from Hydrogels

Controlled Release Drug Delivery from Hydrogels Controlled Release Drug Delivery from Hydrogels Teacher s Guide Keith Neeves CSIP Graduate Fellow Cornell University 1 Overview The objective of this project is to introduce students to the concepts of

More information

Eurofins ADME BIOANALYSES Your partner in drug development

Eurofins ADME BIOANALYSES Your partner in drug development Eurofins ADME BIOANALYSES Your partner in drug development Since 1987, you have placed your confidence in us. Our responsibility, to which my staff and I commit, is to consistently provide you with relevant

More information

Reducing Non-Specific Binding in Surface Plasmon Resonance Experiments

Reducing Non-Specific Binding in Surface Plasmon Resonance Experiments 1 Reducing Non-Specific Binding in Surface Plasmon Resonance Experiments SUMMARY Reducing non-specific binding (NSB) is essential to generating accurate data with SPR The effect of bovine serum albumin,

More information

Platelet Refractoriness: The Basics. Martin H. Bluth, MD, PhD

Platelet Refractoriness: The Basics. Martin H. Bluth, MD, PhD Platelet Refractoriness: The Basics Martin H. Bluth, MD, PhD Complete Toxicology Laboratories, LLC Objectives Define platelet refractoriness and associated conditions that may cause platelet refractoriness.

More information

European Medicines Agency Evaluation of Medicines for Human Use COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT

European Medicines Agency Evaluation of Medicines for Human Use COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT European Medicines Agency Evaluation of Medicines for Human Use London, 27 July 2005 EMEA/CHMP/89249/2004 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT Guideline on the Clinical Investigation

More information

Bioavailability and Bioequivalence Studies

Bioavailability and Bioequivalence Studies Bioavailability and Bioequivalence Studies Standard Approach Part I: Design and Conduct H. Rettig, Ph.D. LLC www.ivivc.com Note for Guidance on the Investigation of Bioavailability and Bioequivalence CPMP/EWP/QWP/1401/98

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency Evaluation of Medicines for Human Use London, 29 July 2004 CPMP/BPWG/1089/00 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE CLINICAL INVESTIGATION OF PLASMA

More information

Properties of Matter. Chemical Properties and Effects on Pollutant Fate. Characteristics of Chemical Changes. Physical Characteristics

Properties of Matter. Chemical Properties and Effects on Pollutant Fate. Characteristics of Chemical Changes. Physical Characteristics Properties of Matter Chemical Properties and Effects on Pollutant Fate Physical Characteristics Characteristics of Chemical Changes Melting point Boiling point Vapor pressure Color State (solid, liquid,

More information

Cycles of vascular plexus formation within the nephrogenic zone of the developing mouse kidney

Cycles of vascular plexus formation within the nephrogenic zone of the developing mouse kidney 1 Supplementary text and data for: 2 3 4 5 Cycles of vascular plexus formation within the nephrogenic zone of the developing mouse kidney Authors: David A. D. Munro 1*, Peter Hohenstein 2, and Jamie A.

More information

Modeling and simulation of drug release through polymer hydrogels. Shantanu Maheshwari, Sivakumar Cherlo, Rama Subba Thavva and Venkataramana Runkana

Modeling and simulation of drug release through polymer hydrogels. Shantanu Maheshwari, Sivakumar Cherlo, Rama Subba Thavva and Venkataramana Runkana Modeling and simulation of drug release through polymer hydrogels Shantanu Maheshwari, Sivakumar Cherlo, Rama Subba Thavva and Venkataramana Runkana 1 Drug delivery: Key challenges Oral delivery Currently,

More information

Enzymes Part III: regulation I. Dr. Mamoun Ahram Summer, 2017

Enzymes Part III: regulation I. Dr. Mamoun Ahram Summer, 2017 Enzymes Part III: regulation I Dr. Mamoun Ahram Summer, 2017 Mechanisms of regulation Expression of isoenzymes Regulation of enzymatic activity Inhibitors Conformational changes Allostery Modulators Reversible

More information

Thursday 26 May 2016 Afternoon Time allowed: 1 hour 30 minutes

Thursday 26 May 2016 Afternoon Time allowed: 1 hour 30 minutes Please write clearly in block capitals. Centre number Candidate number Surname Forename(s) Candidate signature AS BIOLOGY Paper 1 Thursday 26 May 2016 Afternoon Time allowed: 1 hour 30 minutes Materials

More information

Proteomic analysis of biological fluids

Proteomic analysis of biological fluids Proteomic analysis of biological fluids Anne Gonzalez, CNRS-IPBS, Toulouse Équipe «Analyse Protéomique et Spectrométrie de Masse des Biomolécules» Odile Schiltz-Bernard Monsarrat Workshop «Protéomique

More information

Formulation Development of New Chemical Entities (NCEs) Dr. Mariella Artusi Pharmaceutical Development Dept. Monza

Formulation Development of New Chemical Entities (NCEs) Dr. Mariella Artusi Pharmaceutical Development Dept. Monza Formulation Development of New Chemical Entities (NCEs) Dr. Mariella Artusi Pharmaceutical Development Dept. Monza HorizonChem 2018, March, 6th 2018 1 Content Rottapharm Biotech : Company Overview Formulation

More information

Pharmacokinetics as applied to in vitro and animal models

Pharmacokinetics as applied to in vitro and animal models Pharmacokinetics as applied to in vitro and animal models Michael R. Jacobs, MD, PhD Case Western Reserve University University Hospitals of Cleveland Cleveland, OH Topics In vitro pharmacodynamic models

More information

DETERMINATION OF PROTEIN BINDING BY UPLC/MS/MS

DETERMINATION OF PROTEIN BINDING BY UPLC/MS/MS DETERMINATION OF PROTEIN BINDING BY UPLC/MS/MS Darcy Shave and Pete Alden Waters Corporation, Milford, MA, U.S.A. INTRODUCTION Plasma protein binding (PPB) can significantly affect the therapeutic action

More information

Antibodies and Antigens in the Blood Bank 9/7/2015 NAHLA BAKHAMIS 1

Antibodies and Antigens in the Blood Bank 9/7/2015 NAHLA BAKHAMIS 1 Antibodies and Antigens in the Blood Bank NAHLA BAKHAMIS 9/7/2015 NAHLA BAKHAMIS 1 Outline Antibodies structure, classes and functions Most important Abs in the blood bank effective roles of Abs Zeta potential

More information

Recent FDA Guidance For Industry; BCS Class 1 and 3 August 2015

Recent FDA Guidance For Industry; BCS Class 1 and 3 August 2015 Recent FDA Guidance For Industry; BCS Class 1 and 3 August 2015 Bryan Crist Scientific Affairs Manager, Agilent Technologies, Dissolution Systems Dissolution Exchange WebEx Bryan.crist@agilent.com August,

More information

Drugs used in Thromboembolic Disease. Munir Gharaibeh, MD, PhD, MHPE Department of Pharmacology Faculty of Medicine October 2014

Drugs used in Thromboembolic Disease. Munir Gharaibeh, MD, PhD, MHPE Department of Pharmacology Faculty of Medicine October 2014 Drugs used in Thromboembolic Disease Munir Gharaibeh, MD, PhD, MHPE Department of Pharmacology Faculty of Medicine October 2014 Drugs used in Thromboembolic Disease Anticoagulants: Heparin. Oral anticoagulants.

More information

a Ag but activity of silver ion in the membrane phase (σ)=1 Therefore, overall ISE cells containing such a membrane has and

a Ag but activity of silver ion in the membrane phase (σ)=1 Therefore, overall ISE cells containing such a membrane has and Ag 2 S -based membranes behave as ion-exchangers in which Ag + conduct charge through membranes Membrane has no diffusion potential within---only two phase boundary potentials at each side of the pressed

More information

Singapore nanotechnology combats fatal brain infections

Singapore nanotechnology combats fatal brain infections P ublic release date: 28-Jun-2009 Contact: Cathy Yarbrough sciencematter@yahoo.com 858-243-1814 Agency for Science, Technology and Research (A*STAR), Singapore Singapore nanotechnology combats fatal brain

More information

Signaled drug delivery and transport across the blood-brain barrier

Signaled drug delivery and transport across the blood-brain barrier Signaled drug delivery and transport across the blood-brain barrier Peter Hinow Ami Radunskaya Sean M. Mackay John N. J. Reynolds Morgan Schroeder Eng Wui Tan Ian G. Tucker September 30, 2015 Abstract

More information

Bioreactors in tissue engineering

Bioreactors in tissue engineering Bioreactors in tissue engineering S. Swaminathan Director Centre for Nanotechnology & Advanced Biomaterials School of Chemical & Biotechnology SASTRA University Thanjavur 613 401 Tamil Nadu Joint Initiative

More information

Chancen und Limitationen von PK/PD Modellen

Chancen und Limitationen von PK/PD Modellen Chancen und Limitationen von PK/PD Modellen Stephan Schmidt, Ph.D. Center for Pharmacometrics and Systems Pharmacology (CPSP), University of Florida, Orlando, USA 23. Jahrestagung der Pau-Ehrlich-Gesellschaft

More information

Overview of Anatomy and Physioloy II Second Year Students

Overview of Anatomy and Physioloy II Second Year Students University of Baghdad College of Nursing Department of Basic Medical Sciences Overview of Anatomy and Physioloy II Second Year Students Asaad Ismail Ahmad, Ph.D. Asaad Ismail Ahmad, Ph.D. Electrolyte and

More information

KFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar

KFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar KFDA Regulatory Framework on Biopharmaceuticals - Focus on Biosimilar Kyung-Min Baek, Ph.D. Recombinant Protein Products Division Korea Food and Drug Administration(KFDA) Biopharmaceuticals A biopharmaceutical

More information

Cambridge International Examinations Cambridge International Advanced Subsidiary and Advanced Level

Cambridge International Examinations Cambridge International Advanced Subsidiary and Advanced Level Cambridge International Examinations Cambridge International Advanced Subsidiary and Advanced Level *4506784563* BIOLOGY 9700/22 Paper 2 AS Level Structured Questions February/March 2017 1 hour 15 minutes

More information

Proteins Higher Order Structures

Proteins Higher Order Structures Proteins Higher Order Structures Dr. Mohammad Alsenaidy Department of Pharmaceutics College of Pharmacy King Saud University Office: AA 101 msenaidy@ksu.edu.sa Previously on PHT 426!! Protein Structures

More information

Note: for laboratory research use only. RNA High-purity Total RNA Rapid Extraction Kit (Spin-column) Signalway Biotechnology

Note: for laboratory research use only. RNA High-purity Total RNA Rapid Extraction Kit (Spin-column) Signalway Biotechnology Note: for laboratory research use only RNA High-purity Total RNA Rapid Extraction Kit (Spin-column) Cat. #: RP1202 (50preps) Signalway Biotechnology I. Kit Content, Storage Condition and Stability Content

More information

Students will predict the net movement of molecules across a semipermeable membrane.

Students will predict the net movement of molecules across a semipermeable membrane. Edvo-Kit #S-74 What is Osmosis? S-74 Experiment Objective: Students will predict the net movement of molecules across a semipermeable membrane. Students will defi ne what molecules move during diffusion

More information

Pharmacokinetic & Pharmacodynamic Data Analysis

Pharmacokinetic & Pharmacodynamic Data Analysis Pharmacokinetic & Pharmacodynamic Data Analysis CONCEPTS AND APPLICATIONS 4TH EDITION REVISED AND EXPANDED Table of Contents 1. 1.1 1.2 1.3 1.4 1.5 2. 2.1 2.2 2.2.1 2.2.2 2.2.3 2.2.4 2.2.5 2.2.6 2.2.7

More information

Molecular Imaging: Definition, Overview and Goals

Molecular Imaging: Definition, Overview and Goals This tutorial will define what is currently considered molecular imaging. It will provide history and an overview, discuss the goals and the advantages of molecular imaging. It will clarify what is and

More information

drug discovery: Where are we now? How did we RSC February 2013

drug discovery: Where are we now? How did we RSC February 2013 The role of pharmacokinetics in drug discovery: Where are we now? How did we get th here??where are we going? Peter Webborn RSC February 2013 Why conduct PK studies in animals? The primary purpose of pre-clinical

More information

C-type natriuretic peptide signalling and cardiovascular disease Adrian Hobbs

C-type natriuretic peptide signalling and cardiovascular disease Adrian Hobbs C-type natriuretic peptide signalling and cardiovascular disease Adrian Hobbs Professor of Cardiovascular Pharmacology William Harvey Research Institute Barts & The London School of Medicine & Dentistry

More information

Workshop: Applying Exposure Science to Increase the Utility of Non-Animal Data in Efficacy and Safety Testing, 16 Feb. 2017

Workshop: Applying Exposure Science to Increase the Utility of Non-Animal Data in Efficacy and Safety Testing, 16 Feb. 2017 Workshop: Applying Exposure Science to Increase the Utility of Non-Animal Data in Efficacy and Safety Testing, 16 Feb. 2017 Presentation Outline Should we account for kinetics in vitro and in vivo for

More information

The Five Key Elements of a Successful Metabolomics Study

The Five Key Elements of a Successful Metabolomics Study The Five Key Elements of a Successful Metabolomics Study Metabolomics: Completing the Biological Picture Metabolomics is offering new insights into systems biology, empowering biomarker discovery, and

More information

TECHNICAL BULLETIN. CompoZr ADME/Tox Cell Lines Caco-2 BCRP Knockout Cell Line 24 Well Assay Ready Plate

TECHNICAL BULLETIN. CompoZr ADME/Tox Cell Lines Caco-2 BCRP Knockout Cell Line 24 Well Assay Ready Plate CompoZr ADME/Tox Cell Lines Caco-2 BCRP Knockout Cell Line 24 Well Assay Ready Plate Catalog Number MTOX1002P24 Store at Room Temperature TECHNICAL BULLETIN Product Description CompoZr zinc finger nuclease

More information

RapidFACT: Accelerated Formulation Development for Poorly Soluble Drugs and Modified Release Products

RapidFACT: Accelerated Formulation Development for Poorly Soluble Drugs and Modified Release Products RapidFACT: Accelerated Formulation Development for Poorly Soluble Drugs and Modified Release Products Kevin Kane, Scientific Director, BCP 7 th Annual Global Drug Delivery & Formulation Summit 28 th August

More information

Injectable modified release products

Injectable modified release products Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1) Injectable modified release products Dr Sotiris Michaleas, National Expert for the

More information

CAPILLARY PERMEABILITY TO NARROW-RANGE MACROMOLECULAR DEXTRANS AT NORMAL AND HYPOBARIC PRESSURES

CAPILLARY PERMEABILITY TO NARROW-RANGE MACROMOLECULAR DEXTRANS AT NORMAL AND HYPOBARIC PRESSURES CAPILLARY PERMEABILITY TO NARROW-RANGE MACROMOLECULAR DEXTRANS AT NORMAL AND HYPOBARIC PRESSURES APPROVED: Major Professor Minor Professor Comnwttee Mepvper Director of the Department of Biology Dean (of

More information

CRYSTAL CITY V REDUX: GUIDANCE FOR INDUSTRY BIOANALYTICAL METHOD VALIDATION DRAFT GUIDANCE (2013) VI. ADDITIONAL ISSUES

CRYSTAL CITY V REDUX: GUIDANCE FOR INDUSTRY BIOANALYTICAL METHOD VALIDATION DRAFT GUIDANCE (2013) VI. ADDITIONAL ISSUES CRYSTAL CITY V REDUX: GUIDANCE FOR INDUSTRY BIOANALYTICAL METHOD VALIDATION DRAFT GUIDANCE (2013) VI. ADDITIONAL ISSUES DELAWARE VALLEY DRUG METABOLISM DISCUSSION GROUP STEVE PICCOLI, BMS RAND JENKINS,

More information

In Vitro Angiogenesis Assay Kit

In Vitro Angiogenesis Assay Kit In Vitro Angiogenesis Assay Kit Catalog Number KA1323 100 assays Version: 02 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Background... 3 Principle of the Assay...

More information

Biotechnology Explorer

Biotechnology Explorer Biotechnology Explorer Size Exclusion Chromatography Instruction Manual Catalog Number 166-0008-EDU www.bio-rad.com For Technical Service Call Your Local Bio-Rad Office or in the U.S. Call 1-800-4BIORAD

More information

Stem Cells. Part 1: What is a Stem Cell? STO Stem cells are unspecialized. What does this mean?

Stem Cells. Part 1: What is a Stem Cell? STO Stem cells are unspecialized. What does this mean? STO-120 Stem Cells Part 1: What is a Stem Cell? Stem cells differ from other kinds of cells in the body. When a stem cell divides by mitosis, each new cell has the potential to either remain a stem cell

More information

Xeno-Free Systems for hesc & hipsc. Facilitating the shift from Stem Cell Research to Clinical Applications

Xeno-Free Systems for hesc & hipsc. Facilitating the shift from Stem Cell Research to Clinical Applications Xeno-Free Systems for hesc & hipsc Facilitating the shift from Stem Cell Research to Clinical Applications NutriStem Defined, xeno-free (XF), serum-free media (SFM) specially formulated for growth and

More information

In vitro Human Umbilical Vein Endothelial Cells (HUVEC) Tube-formation Assay. Josephine MY Ko and Maria Li Lung *

In vitro Human Umbilical Vein Endothelial Cells (HUVEC) Tube-formation Assay. Josephine MY Ko and Maria Li Lung * In vitro Human Umbilical Vein Endothelial Cells (HUVEC) Tube-formation Assay Josephine MY Ko and Maria Li Lung * Clinical Oncology Department, The Univerisity of Hong Kong, Hong Kong, Hong Kong SAR *For

More information

Pelagia Research Library

Pelagia Research Library Available online at www.pelagiaresearchlibrary.com Der Pharmacia Sinica, 2012, 3 (1):76-92 Strategic Drug Delivery Targeted to the Brain: A Review Sandipan Roy ISSN: 0976-8688 CODEN (USA): PSHIBD Dr.Reddy

More information

DIFFERENT APPROACHES FOR IMPROVING SKIN ACCUMULATION OF CLOBETASOL-17-PROPIONATE

DIFFERENT APPROACHES FOR IMPROVING SKIN ACCUMULATION OF CLOBETASOL-17-PROPIONATE DIFFERENT APPROACHES FOR IMPROVING SKIN ACCUMULATION OF CLOBETASOL-17-PROPIONATE Taner ŞENYİĞİT*, Cristina PADULA**, Özgen ÖZER*, Patrizia SANTI** *Ege University, Faculty of Pharmacy, Department of Pharmaceutical

More information

**MATERIAL SAFETY DATA SHEET**

**MATERIAL SAFETY DATA SHEET** Date Issued: August 19, 2009 Version: 5.0 Supersedes: August 8, 2006 Page 1 of 5 Section 1 Product and Company Identification Product Name: Herceptin Chemical Name: Anti-p185 HER2 Chemical Family: High

More information

Official Letter from the DOH

Official Letter from the DOH Issued Date 2009/04/02 Issued by DOH Ref. No 0980316268 RE The DOH issued an official letter to announce the implementation of the Guideline for BA/BE Studies on April 2, 2009 (Ref. No. 0980316265). Please

More information

Chapter 7: Control of Microbial Growth

Chapter 7: Control of Microbial Growth Chapter 7: Control of Microbial Growth 1. Physical Methods 2. Chemical methods Important Terminology sterilization > commercial sterilization > disinfection = antisepsis > degerming > sanitization Also,

More information

Important Terminology

Important Terminology Chapter 7: Control of Microbial Growth 1. Physical Methods 2. Chemical methods Important Terminology sterilization > commercial sterilization > disinfection = antisepsis > degerming > sanitization Also,

More information

Post-Approval Change Regulations in Japan

Post-Approval Change Regulations in Japan Post-Approval Change Regulations in Japan Pharmaceuticals and Medical Devices Agency Office of Cellular and Tissue-based Products Futaba Honda, Ph.D. Agenda Application Forms and attached documents for

More information

CHAPTER 3 ANTIBODY STRUCTURE I

CHAPTER 3 ANTIBODY STRUCTURE I CHAPTER 3 ANTIBODY STRUCTURE I See APPENDIX: (3) OUCHTERLONY ANALYSIS; (6), EQUILIBRIUM DIALYSIS; (7) CROSS-REACTIVITY Electrophoretic separation of serum proteins identifies the GAMMA-GLOBULIN fraction

More information

Voltage clamp and patch-clamp techniques

Voltage clamp and patch-clamp techniques Voltage clamp and patch-clamp techniques Dr. Nilofar Khan Objectives Historical background Voltage Clamp Theory Variations of voltage clamp Patch-clamp Principal Patch-clamp configurations Applications

More information

INTEGRATED STUDIES, SCIENCE AND BUSINESS VALLEY SANTAKA CENTRE FOR THE ADVANCED PHARMACEUTICAL AND HEALTH TECHNOLOGIES.

INTEGRATED STUDIES, SCIENCE AND BUSINESS VALLEY SANTAKA CENTRE FOR THE ADVANCED PHARMACEUTICAL AND HEALTH TECHNOLOGIES. 1 INTEGRATED STUDIES, SCIENCE AND BUSINESS VALLEY SANTAKA CENTRE FOR THE ADVANCED PHARMACEUTICAL AND HEALTH TECHNOLOGIES www.lsmuni.lt 2 3 About Lithuanian University of Health Sciences Lithuanian University

More information

VEHICULATION OF SUBSTANCES ACROSS THE BLOOD-BRAIN BARRIER MEDIATED BY MOLECULAR TROJAN HORSES

VEHICULATION OF SUBSTANCES ACROSS THE BLOOD-BRAIN BARRIER MEDIATED BY MOLECULAR TROJAN HORSES VEHICULATION OF SUBSTANCES ACROSS THE BLOOD-BRAIN BARRIER MEDIATED BY MOLECULAR TROJAN HORSES MAIN SCOPE: PHYSIOLOGY AND PHYSIOPATHOLOGY SECONDARY SCOPES: 1. PHARMACOLOGY AND THERAPEUTICS 2. CELLULAR BIOLOGY

More information

GE Healthcare. Vivid S6. Cardiovascular ultrasound system

GE Healthcare. Vivid S6. Cardiovascular ultrasound system GE Healthcare Vivid S6 Cardiovascular ultrasound system Taking care of everyone. Strong performance and innovative miniaturization make the Vivid S6 a highly desirable system for a variety of clinical

More information

Immunoglobulins: Structure and Function

Immunoglobulins: Structure and Function Immunoglobulins: Structure and Function Immunoglobulins:Structure and Function Definition: Glycoprotein molecules that are produced by plasma cells in response to an immunogen and which function as antibodies

More information

BCP Albumin Assay Kit

BCP Albumin Assay Kit BCP Albumin Assay Kit Catalog Number KA1613 250 assays Version: 04 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 General Information...

More information

Introduction to Pharmacokinetic Modeling

Introduction to Pharmacokinetic Modeling Introduction to Pharmacokinetic Modeling Introductory PBPK Modeling Tutorial PaSiPhIC July 13, 2011 Harvey J. Clewell, PhD, DABT Director, Center for Human Health Assessment The Hamner Institutes for Health

More information

Drug Delivery to the Brain

Drug Delivery to the Brain Journal of Cerebral Blood Flow and Metabolism 17:713-731 1997 The International Society of Cerebral Blood Flow and Metabolism Published by Lippincott-Raven Publishers. Philadelphia Review Article Drug

More information

Membrane Filtration Technology: Meeting Today s Water Treatment Challenges

Membrane Filtration Technology: Meeting Today s Water Treatment Challenges Membrane Filtration Technology: Meeting Today s Water Treatment Challenges Growing global demand for clean water and increasing environmental concerns make membrane filtration the technology of choice

More information

Predicting Tissue Distribution & Clearance of Antibody Formats to Improve Selectivity of Targeted Therapies

Predicting Tissue Distribution & Clearance of Antibody Formats to Improve Selectivity of Targeted Therapies Predicting Tissue Distribution & Clearance of Antibody Formats to Improve Selectivity of Targeted Therapies Ben-Fillippo Krippendorff, Roche Innovation Center Basel ben-fillippo.krippendorff@roche.com

More information

Biopharmaceuticals - Current FDA & EMAs Regulations on glycan analysis

Biopharmaceuticals - Current FDA & EMAs Regulations on glycan analysis Biopharmaceuticals - Current FDA & EMAs Regulations on glycan analysis Jayesh Kattla, PhD March 2015 Gothenburg & Copenhagen 2013 Waters Corporation 1 Hope and Risk 2013 Waters Corporation 2 The total

More information

STRUCTURE AND FUNCTION OF PLASMA PROTEINS VOLUME 1

STRUCTURE AND FUNCTION OF PLASMA PROTEINS VOLUME 1 STRUCTURE AND FUNCTION OF PLASMA PROTEINS VOLUME 1 STRUCTURE AND FUNCTION OF PLASMA PROTEINS VOLUME 1 Edited by A. C. Allison Clinical Research Centre Watford Road Harrow Middlesex PLENUM PRESS LONDON

More information